Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma
2006-004500-40Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in non-Hodgkin lymphoma (NHL), sponsored by Celgene Corporation. Primary endpoint: Response rate. Started Dec 2006; status: terminated.
02
Drugs
lenalidomide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2006-004500-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004500-40.